S100A12 and the S100/Calgranulins: Emerging Biomarkers for Atherosclerosis and Possibly Therapeutic Targets

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 12, 2015, Pages 2496-2507

  Oesterle, Adam ^a   Hofmann Bowman, Marion A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Apolipoprotein E; atherosclerosis; coronary artery disease; inflammation; S100 calgranulins; S100A12

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTIINFLAMMATORY AGENT; APOLIPOPROTEIN E; CALGRANULIN; CALGRANULIN A; CALGRANULIN B; INTERLEUKIN 6; LAQUINIMOD; MONOCYTE CHEMOTACTIC PROTEIN 1; PAQUINIMOD; PROTEIN S 100; S100A12 PROTEIN; TASQUINIMOD; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; AGER PROTEIN, HUMAN; AUTACOID; BIOLOGICAL MARKER; CALGRANULIN C; S100A12 PROTEIN, HUMAN;

ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CHROMOSOME 3; CORONARY ARTERY DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; GENETIC ASSOCIATION; HUMAN; INFLAMMATORY DISEASE; MULTIPLE SCLEROSIS; NONHUMAN; OBESITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 3 CLINICAL TRIAL (TOPIC); POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOOTH MUSCLE FIBER; TRANSGENIC MOUSE; VASCULAR DISEASE; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; GENETICS; INFLAMMATION; KNOCKOUT MOUSE; METABOLISM; MOLECULARLY TARGETED THERAPY; PREDICTIVE VALUE; PROGNOSIS; SIGNAL TRANSDUCTION;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANIMALS; ANTI-INFLAMMATORY AGENTS; ATHEROSCLEROSIS; BIOMARKERS; CALGRANULIN A; CALGRANULIN B; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; S100A12 PROTEIN; SIGNAL TRANSDUCTION;

EID: 84948099799     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.302072     Document Type: Article

References (94)

1. Mendis S, Davis S, Norrving B. Organizational update: the world health organization global status Report on noncommunicable Diseases 2014; one more landmark step in the combat against stroke and vascular disease. Stroke 2015;46(5):121-122.
2. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:2045-2051. doi: 10.1161/ATVBAHA.108.179705.
3. Hofmann Bowman MA, Schmidt AM. The next generation of RAGE modulators: implications for soluble RAGE therapies in vascular inflammation. J Mol Med (Berl). 2013;91:1329-1331. doi: 10.1007/s00109-013-1097-y.
4. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397. doi: 10.1056/NEJMoa032804.
5. Sarwar N, Butterworth AS, Freitag DF et al; IL6R Genetics Consortium Emerging Risk Factors Collaboration. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012;379:1205-1213. doi: 10.1016/S0140-6736(11)61931-4.
6. Jefferis BJ, Papacosta O, Owen CG, Wannamethee SG, Humphries SE, Woodward M, Lennon LT, Thomson A, Welsh P, Rumley A, Lowe GD, Whincup PH. Interleukin 18 and coronary heart disease: prospective study and systematic review. Atherosclerosis. 2011;217:227-233. doi: 10.1016/j.atherosclerosis.2011.03.015.
7. Kavousi M, Elias-Smale S, Rutten JH, et al. Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study. Ann Intern Med. 2012;156:438-444. doi: 10.7326/0003-4819-156-6-201203200-00006.
8. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207. doi: 10.1056/NEJMoa0807646.
9. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61:404-410. doi: 10.1016/j.jacc.2012.10.027.
10. Everett BM, Pradhan AD, Solomon DH, Paynter N, Macfadyen J, Zaharris E, Gupta M, Clearfield M, Libby P, Hasan AA, Glynn RJ, Ridker PM. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J. 2013;166:199-207.e15. doi: 10.1016/j.ahj.2013.03.018.
11. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1 inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162:597-605. doi: 10.1016/j. ahj.2011.06.012.
12. Yan SF, Ramasamy R, Schmidt AM. The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res. 2010;106:842-853. doi: 10.1161/CIRCRESAHA.109.212217.
13. Schmidt AM, Sahagan B, Nelson RB, Selmer J, Rothlein R, Bell JM. The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer's disease. Curr Opin Investig Drugs. 2009;10:672-680.
14. Rai V, Touré F, Chitayat S, Pei R, Song F, Li Q, Zhang J, Rosario R, Ramasamy R, Chazin WJ, Schmidt AM. Lysophosphatidic acid targets vascular and oncogenic pathways via RAGE signaling. J Exp Med. 2012;209:2339-2350. doi: 10.1084/jem.20120873.
15. Goyette J, Yan WX, Yamen E, Chung YM, Lim SY, Hsu K, Rahimi F, Di Girolamo N, Song C, Jessup W, Kockx M, Bobryshev YV, Freedman SB, Geczy CL. Pleiotropic roles of S100A12 in coronary atherosclerotic plaque formation and rupture. J Immunol. 2009;183:593-603. doi: 10.4049/jimmunol.0900373.
16. Zhao P, Wu M, Yu H, Huang Y, Wang Y, Wang W, Yin W. Serum S100A12 levels are correlated with the presence and severity of coronary artery disease in patients with type 2 diabetes mellitus. J Investig Med. 2013;61:861-866. doi: 10.231/JIM.0b013e318292fb1e.
17. Basta G, Sironi AM, Lazzerini G, Del Turco S, Buzzigoli E, Casolaro A, Natali A, Ferrannini E, Gastaldelli A. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab. 2006;91:4628-4634. doi: 10.1210/jc.2005-2559.
18. Nakashima A, Carrero JJ, Qureshi AR, Miyamoto T, Anderstam B, Bárány P, Heimbürger O, Stenvinkel P, Lindholm B. Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. Clin J Am Soc Nephrol. 2010;5:2213-2219. doi: 10.2215/CJN.03360410.
19. Shiotsu Y, Mori Y, Nishimura M, Sakoda C, Tokoro T, Hatta T, Maki N, Iida K, Iwamoto N, Ono T, Matsuoka E, Kishimoto N, Tamagaki K, Matsubara H, Kosaki A. Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients. Clin J Am Soc Nephrol. 2011;6:718-723. doi: 10.2215/CJN.08310910.
20. Mori Y, Kosaki A, Kishimoto N, Kimura T, Iida K, Fukui M, Nakajima F, Nagahara M, Urakami M, Iwasaka T, Matsubara H. Increased plasma S100A12 (EN-RAGE) levels in hemodialysis patients with atherosclerosis. Am J Nephrol. 2009;29:18-24. doi: 10.1159/000148646.
21. Foell D, Kane D, Bresnihan B, Vogl T, Nacken W, Sorg C, Fitzgerald O, Roth J. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology (Oxford). 2003;42:1383-1389. doi: 10.1093/rheumatology/keg385.
22. Tydén H, Lood C, Gullstrand B, Jönsen A, Nived O, Sturfelt G, Truedsson L, Ivars F, Leanderson T, Bengtsson AA. Increased serum levels of S100A8/A9 and S100A12 are associated with cardiovascular disease in patients with inactive systemic lupus erythematosus. Rheumatology (Oxford). 2013;52:2048-2055. doi: 10.1093/rheumatology/ket263.
23. Hara M, Ando M, Morito T, Nokiba H, Iwasa Y, Tsuchiya K, Nitta K. S100A12 gene expression is increased in peripheral leukocytes in chronic kidney disease stage 4-5 patients with cardiovascular disease. Nephron Clin Pract. 2013;123:202-208. doi: 10.1159/000353808.
24. Donato R, Cannon BR, Sorci G, Riuzzi F, Hsu K, Weber DJ, Geczy CL. Functions of S100 proteins. Curr Mol Med. 2013;13:24-57.
25. Hofmann Bowman MA, Schmidt AM. S100/calgranulins EN-RAGEing the blood vessels: implications for inflammatory responses and atherosclerosis. Am J Cardiovasc Dis. 2011;1:92-100.
26. Vogl T, Pröpper C, Hartmann M, Strey A, Strupat K, van den Bos C, Sorg C, Roth J. S100A12 is expressed exclusively by granulocytes and acts independently from MRP8 and MRP14. J Biol Chem. 1999;274:25291-25296.
27. Averill MM, Kerkhoff C, Bornfeldt KE. S100A8 and S100A9 in cardiovascular biology and disease. Arterioscler Thromb Vasc Biol. 2012;32:223-229. doi: 10.1161/ATVBAHA.111.236927.
28. Urban CF, Ermert D, Schmid M, Abu-Abed U, Goosmann C, Nacken W, Brinkmann V, Jungblut PR, Zychlinsky A. Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans. PLoS Pathog. 2009;5:e1000639. doi: 10.1371/journal.ppat.1000639.
29. De Filippo K, Neill DR, Mathies M, Bangert M, McNeill E, Kadioglu A, Hogg N. A new protective role for S100A9 in regulation of neutrophil recruitment during invasive pneumococcal pneumonia. FASEB J. 2014;28:3600-3608. doi: 10.1096/fj.13-247460.
30. Hofmann MA, Drury S, Fu C, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999;97:889-901.
31. Yan L, Mathew L, Chellan B, Gardner B, Earley J, Puri TS, Hofmann Bowman MA. S100/Calgranulin-mediated inflammation accelerates left ventricular hypertrophy and aortic valve sclerosis in chronic kidney disease in a receptor for advanced glycation end products-dependent manner. Arterioscler Thromb Vasc Biol. 2014;34:1399-1411. doi: 10.1161/ATVBAHA.114.303508.
32. Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, Nacken W, Foell D, van der Poll T, Sorg C, Roth J. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxininduced shock. Nat Med. 2007;13:1042-1049. doi: 10.1038/nm1638.
33. Sroussi HY, Berline J, Palefsky JM. Oxidation of methionine 63 and 83 regulates the effect of S100A9 on the migration of neutrophils in vitro. J Leukoc Biol. 2007;81:818-824. doi: 10.1189/jlb.0706433.
34. Lim SY, Raftery MJ, Goyette J, Hsu K, Geczy CL. Oxidative modifications of S100 proteins: functional regulation by redox. J Leukoc Biol. 2009;86:577-587. doi: 10.1189/jlb.1008608.
35. Yang Z, Yan WX, Cai H, et al. S100A12 provokes mast cell activation: a potential amplification pathway in asthma and innate immunity. J Allergy Clin Immunol. 2007;119:106-114. doi: 10.1016/j. jaci.2006.08.021.
36. Yan WX, Armishaw C, Goyette J, Yang Z, Cai H, Alewood P, Geczy CL. Mast cell and monocyte recruitment by S100A12 and its hinge domain. J Biol Chem. 2008;283:13035-13043. doi: 10.1074/jbc. M710388200.
37. Harja E, Bu DX, Hudson BI, et al. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE/mice. J Clin Invest. 2008;118:183-194. doi: 10.1172/JCI32703.
38. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. 1992;267:14998-15004.
39. Yan L, Bjork P, Butuc R, Gawdzik J, Earley J, Kim G, Hofmann Bowman MA. Beneficial effects of quinoline-3-carboxamide (ABR-215757) on atherosclerotic plaque morphology in S100A12 transgenic ApoE null mice. Atherosclerosis. 2013;228:69-79. doi: 10.1016/j. atherosclerosis.2013.02.023.
40. Srikrishna G, Nayak J, Weigle B, Temme A, Foell D, Hazelwood L, Olsson A, Volkmann N, Hanein D, Freeze HH. Carboxylated N-glycans on RAGE promote S100A12 binding and signaling. J Cell Biochem. 2010;110:645-659. doi: 10.1002/jcb.22575.
41. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ, Jr, Chow WS, Stern D, Schmidt AM. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med. 1998;4:1025-1031. doi: 10.1038/2012.
42. Sakaguchi T, Yan SF, Yan SD, Belov D, Rong LL, Sousa M, Andrassy M, Marso SP, Duda S, Arnold B, Liliensiek B, Nawroth PP, Stern DM, Schmidt AM, Naka Y. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest. 2003;111:959-972. doi: 10.1172/JCI17115.
43. Tae HJ, Kim JM, Park S, et al. The N-glycoform of sRAGE is the key determinant for its therapeutic efficacy to attenuate injury-elicited arterial inflammation and neointimal growth. J Mol Med (Berl). 2013;91:1369-1381. doi: 10.1007/s00109-013-1091-4.
44. Björkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA, Means T, Halmen K, Luster AD, Golenbock DT, Freeman MW. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med. 2004;10:416-421. doi: 10.1038/nm1008.
45. Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer. 2009;9:57-63. doi: 10.1038/nrc2541.
46. Hofmann Bowman MA, Gawdzik J, Bukhari U, Husain AN, Toth PT, Kim G, Earley J, McNally EM. S100A12 in vascular smooth muscle accelerates vascular calcification in apolipoprotein E-null mice by activating an osteogenic gene regulatory program. Arterioscler Thromb Vasc Biol. 2011;31:337-344. doi: 10.1161/ATVBAHA.110.217745.
47. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000;20:1262-1275.
48. Byon CH, Javed A, Dai Q, Kappes JC, Clemens TL, Darley-Usmar VM, McDonald JM, Chen Y. Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling. J Biol Chem. 2008;283:15319-15327. doi: 10.1074/jbc. M800021200.
49. Cmoch A, Strzelecka-Kiliszek A, Palczewska M, Groves P, Pikula S. Matrix vesicles isolated from mineralization-competent Saos-2 cells are selectively enriched with annexins and S100 proteins. Biochem Biophys Res Commun. 2011;412:683-687. doi: 10.1016/j. bbrc.2011.08.025.
50. Hofmann Bowman MA, McNally EM. Genetic pathways of vascular calcification. Trends Cardiovasc Med. 2012;22:93-98. doi: 10.1016/j. tcm.2012.07.002.
51. Kapustin AN, Chatrou ML, Drozdov I, et al. Vascular smooth muscle cell calcification is mediated by regulated exosome secretion. Circ Res. 2015;116:1312-1323. doi: 10.1161/CIRCRESAHA.116.305012.
52. New SE, Aikawa E. Role of extracellular vesicles in de novo mineralization: an additional novel mechanism of cardiovascular calcification. Arterioscler Thromb Vasc Biol. 2013;33:1753-1758. doi: 10.1161/ATVBAHA.112.300128.
53. Gawdzik J, Mathew L, Kim G, Puri TS, Hofmann Bowman MA. Vascular remodeling and arterial calcification are directly mediated by S100A12 (EN-RAGE) in chronic kidney disease. Am J Nephrol. 2011;33:250-259. doi: 10.1159/000324693.
54. Burton DG, Matsubara H, Ikeda K. Pathophysiology of vascular calcification: Pivotal role of cellular senescence in vascular smooth muscle cells. Exp Gerontol. 2010;45:819-824. doi: 10.1016/j.exger.2010.07.005.
55. Hofmann Bowman M, Wilk J, Heydemann A, Kim G, Rehman J, Lodato JA, Raman J, McNally EM. S100A12 mediates aortic wall remodeling and aortic aneurysm. Circ Res. 2010;106:145-154. doi: 10.1161/CIRCRESAHA.109.209486.
56. Burke AP, Kolodgie FD, Zieske A, Fowler DR, Weber DK, Varghese PJ, Farb A, Virmani R. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol. 2004;24:1266-1271. doi: 10.1161/01. ATV.0000131783.74034.97.
57. Das D, Gawdzik J, Dellefave-Castillo L, McNally EM, Husain A, Raman J, Hofmann Bowman MA. S100A12 expression in thoracic aortic aneurysm is associated with increased risk of dissection and perioperative complications. J Am Coll Cardiol. 2012;60:775-785. doi: 10.1016/j. jacc.2012.04.027.
58. Yui S, Nakatani Y, Mikami M. Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity. Biol Pharm Bull. 2003;26:753-760.
59. Sandhu HK, Charlton-Ouw KM, Leake SS, Azizzadeh A, Nguyen TC, Estrera AL, Safi HJ, Miller CC. Is the seasonal variation in acute aortic dissection occurrence associated with flu activity Circulation. 2014;130:A19298.
60. Nagareddy PR, Murphy AJ, Stirzaker RA, Hu Y, Yu S, Miller RG, Ramkhelawon B, Distel E, Westerterp M, Huang LS, Schmidt AM, Orchard TJ, Fisher EA, Tall AR, Goldberg IJ. Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab. 2013;17:695-708. doi: 10.1016/j.cmet.2013.04.001.
61. Dutta P, Courties G, Wei Y, et al. Myocardial infarction accelerates atherosclerosis. Nature. 2012;487:325-329. doi: 10.1038/nature11260.
62. Karussis DM, Lehmann D, Slavin S, Vourka-Karussis U, Mizrachi-Koll R, Ovadia H, Kalland T, Abramsky O. Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proc Natl Acad Sci USA. 1993;90:6400-6404.
63. Tarkowski A, Gunnarsson K, Stålhandske T. Effects of LS-2616 administration upon the autoimmune disease of (NZB x NZW) F1 hybrid mice. Immunology. 1986;59:589-594.
64. Björk J, Kleinau S. Paradoxical effects of LS-2616 (Linomide) treatment in the type II collagen arthritis model in mice. Agents Actions. 1989;27:319-321.
65. Brunmark C, Runström A, Ohlsson L, Sparre B, Brodin T, Aström M, Hedlund G. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol. 2002;130:163-172.
66. Björk P, Björk A, Vogl T, Stenström M, Liberg D, Olsson A, Roth J, Ivars F, Leanderson T. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol. 2009;7:e97. doi: 10.1371/journal. pbio.1000097.
67. Kosaki A, Hasegawa T, Kimura T, Iida K, Hitomi J, Matsubara H, Mori Y, Okigaki M, Toyoda N, Masaki H, Inoue-Shibata M, Nishikawa M, Iwasaka T. Increased plasma S100A12 (EN-RAGE) levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2004;89:5423-5428. doi: 10.1210/jc.2003-032223.
68. Wingrove JA, Daniels SE, Sehnert AJ, Tingley W, Elashoff MR, Rosenberg S, Buellesfeld L, Grube E, Newby LK, Ginsburg GS, Kraus WE. Correlation of peripheral-blood gene expression with the extent of coronary artery stenosis. Circ Cardiovasc Genet. 2008;1:31-38. doi: 10.1161/CIRCGENETICS.108.782730.
69. Rosenberg S, Elashoff MR, Beineke P, et al.; PREDICT (Personalized Risk Evaluation and Diagnosis in the Coronary Tree) Investigators. Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. Ann Intern Med. 2010;153:425-434. doi: 10.7326/0003-4819-153-7-201010050-00005.
70. Saito T, Hojo Y, Ogoyama Y, Hirose M, Ikemoto T, Katsuki T, Shimada K, Kario K. S100A12 as a marker to predict cardiovascular events in patients with chronic coronary artery disease. Circ J. 2012;76:2647-2652.
71. Liu J, Ren YG, Zhang LH, Tong YW, Kang L. Serum S100A12 concentrations are correlated with angiographic coronary lesion complexity in patients with coronary artery disease. Scand J Clin Lab Invest. 2014;74:149-154. doi: 10.3109/00365513.2013.864786.
72. Ligthart S, Sedaghat S, Ikram MA, Hofman A, Franco OH, Dehghan A. EN-RAGE: a novel inflammatory marker for incident coronary heart disease. Arterioscler Thromb Vasc Biol. 2014;34:2695-2699. doi: 10.1161/ATVBAHA.114.304306.
73. Choi KM, Han KA, Ahn HJ, Hwang SY, Hong HC, Choi HY, Yang SJ, Yoo HJ, Baik SH, Choi DS, Min KW. Effects of exercise on sRAGE levels and cardiometabolic risk factors in patients with type 2 diabetes: a randomized controlled trial. J Clin Endocrinol Metab. 2012;97:3751-3758. doi: 10.1210/jc.2012-1951.
74. Ellsworth DL, Croft DT, Jr, Weyandt J, Sturtz LA, Blackburn HL, Burke A, Haberkorn MJ, McDyer FA, Jellema GL, van Laar R, Mamula KA, Chen Y, Vernalis MN. Intensive cardiovascular risk reduction induces sustainable changes in expression of genes and pathways important to vascular function. Circ Cardiovasc Genet. 2014;7:151-160. doi: 10.1161/CIRCGENETICS.113.000121.
75. Mortensen OH, Nielsen AR, Erikstrup C, Plomgaard P, Fischer CP, Krogh-Madsen R, Lindegaard B, Petersen AM, Taudorf S, Pedersen BK. Calprotectin-a novel marker of obesity. PLoS One. 2009;4:e7419. doi: 10.1371/journal.pone.0007419.
76. Catalán V, Gómez-Ambrosi J, Rodríguez A, Ramírez B, Rotellar F, Valentí V, Silva C, Gil MJ, Fernández-Real JM, Salvador J, Frühbeck G. Increased levels of calprotectin in obesity are related to macrophage content: impact on inflammation and effect of weight loss. Mol Med. 2011;17:1157-1167. doi: 10.2119/molmed.2011.00144.
77. Chagnon YC, Rice T, Pérusse L, Borecki IB, Ho-Kim MA, Lacaille M, Paré C, Bouchard L, Gagnon J, Leon AS, Skinner JS, Wilmore JH, Rao DC, Bouchard C; HERITAGE Family Study. Genomic scan for genes affecting body composition before and after training in Caucasians from HERITAGE. J Appl Physiol (1985). 2001;90:1777-1787.
78. Kim OY, Jo SH, Jang Y, Chae JS, Kim JY, Hyun YJ, Lee JH. G allele at RAGE SNP82 is associated with proinflammatory markers in obese subjects. Nutr Res. 2009;29:106-113. doi: 10.1016/j.nutres.2009.01.006.
79. Hofmann MA, Drury S, Hudson BI, et al. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun. 2002;3:123-135. doi: 10.1038/sj.gene.6363861.
80. Song F, Hurtado del Pozo C, Rosario R, Zou YS, Ananthakrishnan R, Xu X, Patel PR, Benoit VM, Yan SF, Li H, Friedman RA, Kim JK, Ramasamy R, Ferrante AW, Jr, Schmidt AM. RAGE regulates the metabolic and inflammatory response to high-fat feeding in mice. Diabetes. 2014;63:1948-1965. doi: 10.2337/db13-1636.
81. Morrow DA, Wang Y, Croce K, Sakuma M, Sabatine MS, Gao H, Pradhan AD, Healy AM, Buros J, McCabe CH, Libby P, Cannon CP, Braunwald E, Simon DI. Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. Am Heart J. 2008;155:49-55. doi: 10.1016/j.ahj.2007.08.018.
82. Healy AM, Pickard MD, Pradhan AD, et al. Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation. 2006;113:2278-2284. doi: 10.1161/CIRCULATIONAHA.105.607333.
83. Kim JK, Park S, Lee MJ, Song YR, Han SH, Kim SG, Kang SW, Choi KH, Kim HJ, Yoo TH. Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis. Atherosclerosis. 2012;220:208-214. doi: 10.1016/j. atherosclerosis.2011.07.115.
84. Shiotsu Y, Mori Y, Hatta T, Maki N, Iida K, Matsuoka E, Kado H, Ishida R, Kishimoto N, Tamagaki K, Nishimura M, Iwamoto N, Ono T, Matsubara H, Kosaki A. Plasma S100A12 levels and peripheral arterial disease in end-stage renal disease. Nephron Extra. 2011;1:242-250. doi: 10.1159/000335198.
85. Croce K, Gao H, Wang Y, Mooroka T, Sakuma M, Shi C, Sukhova GK, Packard RR, Hogg N, Libby P, Simon DI. Myeloid-related protein-8/14 is critical for the biological response to vascular injury. Circulation. 2009;120:427-436. doi: 10.1161/CIRCULATIONAHA. 108.814582.
86. Tan IL, Lycklama à Nijeholt GJ, Polman CH, Adèr HJ, Barkhof F. Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials. Mult Scler. 2000;6:99-104.
87. Noseworthy JH, Wolinsky JS, Lublin FD, Whitaker JN, Linde A, Gjorstrup P, Sullivan HC. Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators. Neurology. 2000;54:1726-1733.
88. Jönsson S, Andersson G, Fex T, Fristedt T, Hedlund G, Jansson K, Abramo L, Fritzson I, Pekarski O, Runström A, Sandin H, Thuvesson I, Björk A. Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. J Med Chem. 2004;47:2075-2088. doi: 10.1021/jm031044w.
89. Carlsten H, Jonsson C, Bokarewa M, Svensson L, Tarkowski A. The impact of a new immunomodulator oxo-quinoline-3-carboxamide on the progression of experimental lupus. Int Immunopharmacol. 2004;4:1515-1523. doi: 10.1016/j.intimp.2004.07.009.
90. Bengtsson AA, Sturfelt G, Lood C, Rönnblom L, van Vollenhoven RF, Axelsson B, Sparre B, Tuvesson H, Ohman MW, Leanderson T. Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64:1579-1588. doi: 10.1002/art.33493.
91. Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, Filippi M; ALLEGRO Study Group. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012;366:1000-1009. doi: 10.1056/NEJMoa1104318.
92. Vollmer TL, Sorensen PS, Selmaj K, Zipp F, Havrdova E, Cohen JA, Sasson N, Gilgun-Sherki Y, Arnold DL; BRAVO Study Group. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol. 2014;261:773-783. doi: 10.1007/s00415-014-7264-4.
93. Pili R, Häggman M, Stadler WM, Gingrich JR, Assikis VJ, Björk A, Nordle O, Forsberg G, Carducci MA, Armstrong AJ. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol. 2011;29:4022-4028. doi: 10.1200/JCO.2011.35.6295.
94. Shishibori T, Oyama Y, Matsushita O, Yamashita K, Furuichi H, Okabe A, Maeta H, Hata Y, Kobayashi R. Three distinct anti-allergic drugs, amlexanox, cromolyn and tranilast, bind to S100A12 and S100A13 of the S100 protein family. Biochem J. 1999;338(pt 3):583-589.